Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

Lancet

Volumn 353, Issue 9154, 1999, Pages 717-719

  Aithal, Guruprasad P ^a   Day, Christopher P ^a   Kesteven, Patrick J L ^a   Daly, Ann K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450; WARFARIN;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN VARIANT; RISK FACTOR; STATISTICAL ANALYSIS; UNITED KINGDOM;

EID: 0033608466     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)04474-2     Document Type: Article

References (17)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
2. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156: 409-16.
3. Finn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin: the national consortium of anticoagulation. Ann Intern Med 1996; 124: 970-79.
4. James AH, Britt RP, Risking CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992; 45: 704-06.
5. Hallak HO, Wedlund PJ, Modi MW, et al. High clearance of (S)-warfarin resistant subject. Br J Clin Pharmacol 1993; 35: 327-30.
6. Doecke CJ, Cosh DG, Gallus AS. Standardized initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomized trial and risk factors for an excessive warfarin response. Aust NZ J Med 1991; 21: 319-24.
7. Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effects on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5: 389-92.
8. Choonara IA, Cholerton S, Haynes BP, Breckenridge AM, Park BK. Stereoselective interaction between the R-enantiomer of warfarin and cimetidine. Br J Clin Pharmacol 1986; 21: 271-77.
9. Kaminsky LS, Zhang Z-Y. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
10. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6: 429-39.
11. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39-42.
12. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression purification, structural characterization, substrate stereoselectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996; 333: 447-58.
13. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7: 203-10.
14. Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7: 361-67.
15. Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multiallelism. Methods Enzymol 1996; 272: 199-210.
16. Wang S-L, Huang J-D, Lai M-D, Tsai J-J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5: 37-42.
17. Anonymous. How to anticoagulate. Drug Ther Bull 1992; 30: 77-80.